Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Biodistribution/dosimetry compared to overall safety profile.

Val Lewington,Chris Parker,Cecilia Hindorf,Glenn D. Flux,Sarah J. Chittenden,George Sgouros,G. O'Bryan-Tear,Anne-Kirsti Aksnes

Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Biodistribution/dosimetry compared to overall safety profile.

2010

Val Lewington
Chris Parker
Cecilia Hindorf
Glenn D. Flux
Sarah J. Chittenden
George Sgouros
G. O'Bryan-Tear
Anne-Kirsti Aksnes

e15009 Background: Radium-223 chloride (Alpharadin) is a first-in-class targeted alpha-pharmaceutical with a potent and highly targeted antitumor effect on bone metastases. It has shown a promising...

Keywords:

Castration
Prostate cancer
Dosimetry
Alpha (ethology)
Biodistribution
Oncology
Radium-223 chloride
Medicine
Internal medicine
safety profile
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations